Stocks · News reference
On Tuesday, Aytu BioPharma (NASDAQ:AYTU) discussed fourth-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by Benzinga APIs. For real-time
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Aytu BioPharma reported a Q4 loss of $0.05 per share, beating consensus estimates of -$0.22 loss, representing a 77.27% earnings surprise. The company posted revenues of $16.11 million, surpassing consensus by 39.45%. However, the stock has underperformed the market, down 18.3% year-to-date versus the S&P 500's 13.4% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
Aytu BioPharma (NASDAQ:AYTU) reported quarterly sales of $16.106 million which beat the analyst consensus estimate of $12.276 million by 31.20 percent. This is a 6.42 percent increase over sales of $15.135 million the